AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

S. Antonarakis, Emmanuel; Lu, Changxue; Wang, Hao; Luber, Brandon; Nakazawa, Mari; C. Roeser, Jeffrey; Chen, Yan; A. Mohammad, Tabrez; Chen, Yidong; Fedor, Helen; L. Lotan, Tamara; Zheng, Qizhi; M. De Marzo, Angelo; T. Isaacs, John; B. Isaacs, William; Nadal, Rosa; J. Paller, Channing; R. Denmeade, Samuel; A. Carducci, Michael; A. Eisenberger, Mario; Luo, Jun

doi:10.1056/nejmoa1315815

Public

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Published in New England Journal of Medicine • Sep 3, 2014

Authors:

Emmanuel S. Antonarakis

Changxue Lu

Hao Wang

Abstract

BACKGROUND: The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA ...

Subject

Enzalutamide

Medicine

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!